Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Ryo NAKAGAWA"'
Publikováno v:
Heliyon, Vol 10, Iss 15, Pp e34338- (2024)
In order to effectively utilize woody biomass, which has a low abundance density, it is necessary to develop a power generation system that can convert it with high efficiency even with a small capacity as less than 2 MW. For electricity generation,
Externí odkaz:
https://doaj.org/article/f8119e60077c47df90589468ed63df5e
Autor:
Ariki Nagashima, Kenichiro Okimoto, Ryo Nakagawa, Naoki Akizue, Tomoaki Matsumura, Hirotaka Oura, Ryuta Kojima, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Wataru Shiratori, Tatsuya Kaneko, Kengo Kanayama, Yuki Ohta, Takashi Taida, Keiko Saito, Tetsuhiro Chiba, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract The mechanism of metachronous recurrence (MR) after performing endoscopic treatment for early gastric adenocarcinoma (GAC) and eradicating Helicobacter pylori (H. pylori) is unknown. To elucidate the mechanism and risk factors of MR, we anal
Externí odkaz:
https://doaj.org/article/beb00b48e7a64e42951e25662a364e61
Autor:
Koji Komatsu, Kei Sano, Kota Fukai, Ryo Nakagawa, Takashi Nakagawa, Masayuki Tatemichi, Tadashi Nakano
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract This cross-sectional study aimed to investigate the promoting and inhibitory factors of diabetic retinopathy (DR) according to diabetes mellitus (DM) stage using standardized evaluation of fundus images by artificial intelligence (AI). A tot
Externí odkaz:
https://doaj.org/article/7a8d9bb911a74f43929e4a985cf920d8
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 513-520 (2023)
Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecula
Externí odkaz:
https://doaj.org/article/48e468f6fb3749d39b8be35352b06933
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in
Externí odkaz:
https://doaj.org/article/ec4cc9154a2f40df8dcaa61493fe4d89
Autor:
Amelie Hagelauer, Rich Ruby, Shogo Inoue, Victor Plessky, Ken-Ya Hashimoto, Ryo Nakagawa, Jordi Verdu, Pedro de Paco, Amir Mortazawi, Gianluca Piazza, Zachary Schaffer, Ernest Ting-Ta Yen, Thomas Forster, Andreas Tag
Publikováno v:
IEEE Journal of Microwaves, Vol 3, Iss 1, Pp 484-508 (2023)
This paper reviews the latest developments in microwave acoustic wave devices. After an introduction and brief history of bulk acoustic wave (BAW) and surface acoustic wave (SAW) devices, a review is given for guided SAWs and XBARs - two new technolo
Externí odkaz:
https://doaj.org/article/7daa159a0ba44653b94cfb3d0891deb6
Autor:
Shoichi Ishikawa, MD, Shun Matsumura, MD, PhD, Akiko Yana, MD, Clara Kurishima, MD, Yoichi Iwamoto, MD, PhD, Hirotaka Ishido, MD, PhD, Satoshi Masutani, MD, PhD, FAHA, Ryo Nakagawa, MD, PhD, Hideaki Senzaki, MD, PhD, FAHA
Publikováno v:
JTCVS Open, Vol 11, Iss , Pp 388-397 (2022)
Objective: Fontan circulation maintains preload and cardiac output by reducing venous capacitance and increasing central venous pressure (CVP). The resultant congestive end-organ damage affects patient prognosis. Therefore, a better circulatory manag
Externí odkaz:
https://doaj.org/article/ef37703363bd4c6d8c8ff7d2fdfbf772
Autor:
Jun Arai, Yumi Otoyama, Ken-ichi Fujita, Kaku Goto, Masayuki Tojo, Atsushi Katagiri, Hisako Nozawa, Yutaro Kubota, Takehiro Takahashi, Hiroo Ishida, Takuya Tsunoda, Natsumi Matsumoto, Keita Ogawa, Ryo Nakagawa, Ryosuke Muroyama, Naoya Kato, Hitoshi Yoshida
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in
Externí odkaz:
https://doaj.org/article/beacc506008f4c9b88f6ed901d1eff5b
Autor:
Takahiro Seimiya, Tatsunori Suzuki, Takuma Iwata, Takahiro Kishikawa, Kazuma Sekiba, Chikako Shibata, Kazunaga Ishigaki, Hiroaki Fujiwara, Hiroki Oyama, Sachiko Kanai, Tatsuya Sato, Yousuke Nakai, Rei Ishibashi, Masaru Moriyama, Ryo Nakagawa, Hideaki Ijichi, Motoyuki Otsuka, Kazuhiko Koike
Publikováno v:
iScience, Vol 26, Iss 2, Pp 106021- (2023)
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to the difficulty of its diagnosis. Because human satellite II (HSATII) RNA, a satellite repeat RNA, is highly and specifically expressed in human PDAC, the serum HSATII RNA le
Externí odkaz:
https://doaj.org/article/6009bda82b6e4f299aeb85e1fb861a3b